Incremental dialysis: two complementary views.

equivalent renal urea clearance (EKRU) haemodialysis incremental haemodialysis residual kidney urea clearance (Kru) standard Kt/V (stdKt/V)

Journal

Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321

Informations de publication

Date de publication:
Feb 2024
Historique:
received: 20 12 2023
medline: 26 2 2024
pubmed: 26 2 2024
entrez: 26 2 2024
Statut: epublish

Résumé

Franco Casino and Mariana Murea discuss today's knowledge about the 'incremental dialysis' concept. Franco Casino frames the problem by saying that, in the presence of substantial residual kidney function, kidney replacement therapy can begin with low doses and/or frequencies, to be gradually increased to compensate for any subsequent losses of residual kidney function, keeping the total clearance above the minimum levels of adequacy. He remarks that studies so far have documented that this approach is safe. He recognizes that adequate randomized controlled trials (RCTs) are necessary to confirm the safety and simplify and standardize the practical aspects of this approach. Mariana Murea objects that most of the evidence gathered so far primarily derives from retrospective and observational studies, which can be influenced by socioeconomic constraints. She argues for the need for RCTs to provide compelling empirical evidence on the efficacy of incremental dialysis. Nephrologists are still reluctant to adopt this approach for various reasons, including unfamiliarity with the method, lack of practical guidance and financial disincentives. Several countries have ongoing or planned RCTs comparing incremental dialysis with conventional dialysis. These trials can shift the haemodialysis paradigm if they validate the safety and effectiveness of this approach. The moderators believe that the results of ongoing trials must be carefully interpreted, and further validation may be needed across different patient populations or healthcare settings. The ultimate goal is to gather robust evidence that could lead to widespread adoption of incremental haemodialysis, optimizing treatment, reducing overtreatment, preserving resources and improving patients' quality of life.

Identifiants

pubmed: 38404364
doi: 10.1093/ckj/sfae020
pii: sfae020
pmc: PMC10894032
doi:

Types de publication

Journal Article

Langues

eng

Pagination

sfae020

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the ERA.

Déclaration de conflit d'intérêts

J.F. is the Editor-in-Chief of CKJ. C.Z. is member of the Editorial Board of CKJ.

Auteurs

Debaters Francesco Gaetano Casino (DFG)

Department of Internal Medicine, Division of Nephrology, Hospital Madonna delle Grazie, Matera, Italy.

Mariana Murea (M)

Department of Internal Medicine, Section on Nephrology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.

Moderators Jürgen Floege (MJ)

Division of Nephrology and Rheumatology, RWTH Aachen University Hospital, Aachen, Germany.

Carmine Zoccali (C)

Renal Research Institute NY, USA.
BIOGEM, Ariano Irpino, Italy.
IPNET, Reggio Cal, Italy.

Classifications MeSH